Place the Ebasten-FT tablet on the tongue. It will rapidly disperse and can be swallowed immediately with or without water. It can be taken with or without food, but taking it with food may slightly delay absorption.

Ebastine is a selective, long-acting H1-receptor antagonist. It competitively inhibits the binding of histamine to peripheral H1 receptors, thereby preventing histamine-mediated allergic reactions like sneezing, itching, and watery eyes. Ebastine is rapidly metabolized to its active metabolite, carebastine, which is primarily responsible for its antihistaminic effect.

• •Hypersensitivity to ebastine or any of the excipients of the formulation.
• •Children under 12 years of age (for 10 mg tablet, specific age recommendations may vary by product/country).
• •Severe hepatic impairment.

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of the sight and reach of children.

In cases of overdose, symptoms may include increased drowsiness, central nervous system (CNS) depression, or cardiac effects such as QT prolongation. Management involves symptomatic and supportive treatment. There is no specific antidote. Gastric lavage and activated charcoal may be considered in recent ingestions. Monitor vital signs and ECG.

Pregnancy Category B. Studies in animals have not shown teratogenic effects, but human data are limited. Ebasten-FT should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks. Not recommended during lactation as ebastine or its active metabolite may be excreted in breast milk.